The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts.

Correvio Pharma Corp’s (NASDAQ: CORV) NDA for Brinavess, or vernakalant HCl solution, ahead of the Dec. 24 PDUFA action date.” data-reactid=”26″>FDA’s Cardiovascular and Renal Drugs Advisory Committee will discuss Tuesday Correvio Pharma Corp’s (NASDAQ: CORV) NDA for Brinavess, or vernakalant HCl solution, ahead of the Dec. 24 PDUFA action date.

Clinical Readouts ASH Presentations Sunday

GENMAB A/S/S ADR (NASDAQ: GMAB): initial Phase 1 data for HexaBody-DR5/DR5 in solid tumors’ data-reactid=”30″>GENMAB A/S/S ADR (NASDAQ: GMAB): initial Phase 1 data for HexaBody-DR5/DR5 in solid tumors

Uniqure NV (NASDAQ: QURE): Phase 2b data for AMT-061 in hemophilia B’ data-reactid=”32″>Uniqure NV (NASDAQ: QURE): Phase 2b data for AMT-061 in hemophilia B

Bristol-Myers Squibb Co (NYSE: BMY): updated Phase 1 data for liso-cel in chronic lymphocytic leukemia’ data-reactid=”34″>Bristol-Myers Squibb Co (NYSE: BMY): updated Phase 1 data for liso-cel in chronic lymphocytic leukemia

Portola Pharmaceuticals Inc (NASDAQ: PTLA): interim Phase 2a data for cerdulatinib in refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia’ data-reactid=”36″>Portola Pharmaceuticals Inc (NASDAQ: PTLA): interim Phase 2a data for cerdulatinib in refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia

Fortress Biotech (NASDAQ: FBIO) and Mustang Bio Inc (NASDAQ: MBIO): Phase 1 data for MB-106 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia’ data-reactid=”38″>Fortress Biotech (NASDAQ: FBIO) and Mustang Bio Inc (NASDAQ: MBIO): Phase 1 data for MB-106 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS): Phase 1/2 data for vecabrutinib in advanced B-cell malignancies’ data-reactid=”40″>Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS): Phase 1/2 data for vecabrutinib in advanced B-cell malignancies

Alpine Immune Sciences Inc (NASDAQ: ALPN): Phase 1 data for ALPN-101 in healthy volunteers’ data-reactid=”42″>Alpine Immune Sciences Inc (NASDAQ: ALPN): Phase 1 data for ALPN-101 in healthy volunteers

Beigene Ltd (NASDAQ: BGNE): Phase 3 data for zanubrutinib in first-line chronic lymphocytic leukemia or small lymphocytic leukemia’ data-reactid=”44″>Beigene Ltd (NASDAQ: BGNE): Phase 3 data for zanubrutinib in first-line chronic lymphocytic leukemia or small lymphocytic leukemia

Blueprint Medicines Corp (NASDAQ: BPMC): initial Phase 2 data for avapritinib in indolent and smoldering systemic mastocytosis’ data-reactid=”46″>Blueprint Medicines Corp (NASDAQ: BPMC): initial Phase 2 data for avapritinib in indolent and smoldering systemic mastocytosis

LLY): Phase 1/2 data for LOXO-305 in refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin’s lymphomas” data-reactid=”47″>Eli Lilly And Co (NYSE: LLY): Phase 1/2 data for LOXO-305 in refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin’s lymphomas

IMV): Phase 2 data for DPX-Survivac and Merck & Co., Inc. (NYSE: MRK)’s Keytruda in diffuse large cell lymphoma” data-reactid=”48″>Imv Inc (NASDAQ: IMV): Phase 2 data for DPX-Survivac and Merck & Co., Inc. (NYSE: MRK)’s Keytruda in diffuse large cell lymphoma

Amgen, Inc. (NASDAQ: AMGN) & GENMAB: Phase 3 data for krypolis in multiple myeloma (late-breaker abstract)’ data-reactid=”80″>Amgen, Inc. (NASDAQ: AMGN) & GENMAB: Phase 3 data for krypolis in multiple myeloma (late-breaker abstract)

ZLAB) – oral presentation of detailed results from the second interim overall survival analysis form the SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have been previously treated with anti-HER2-targeted therapies (date not confirmed)’ data-reactid=”88″>MacroGenics and Zai Lab Ltd (NASDAQ: ZLAB) – oral presentation of detailed results from the second interim overall survival analysis form the SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have been previously treated with anti-HER2-targeted therapies (date not confirmed)

RHHBY)’s Herceptin and oral chemotherapy Xeloda in HER2+ metastatic breast cancer (Wednesday)” data-reactid=”89″>Seattle Genetics – already-released Phase 2 data for Tucatinib ONT-380 in combination with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)’s Herceptin and oral chemotherapy Xeloda in HER2+ metastatic breast cancer (Wednesday)

GTHX) – additional Phase 1b data for Lerociclib plus AstraZeneca plc (NYSE: AZN)’s Faslodex in ER+ breast cancer (Wednesday)” data-reactid=”90″>G1 Therapeutics Inc (NASDAQ: GTHX) – additional Phase 1b data for Lerociclib plus AstraZeneca plc (NYSE: AZN)’s Faslodex in ER+ breast cancer (Wednesday)

Athenex Inc (NASDAQ: ATNX): Phase 3 data for oraxol in metastatic breast cancer (Friday)’ data-reactid=”93″>Athenex Inc (NASDAQ: ATNX): Phase 3 data for oraxol in metastatic breast cancer (Friday)

ESMO-IO Presentations

Twist Bioscience Corp (NASDAQ: TWST) (Wednesday, after the market close)
Veru Inc (NASDAQ: VERU) (Thursday, before the market open)
Applied DNA Sciences Inc (NASDAQ: APDN) (Thursday, after the market close)’ data-reactid=”98″>Twist Bioscience Corp (NASDAQ: TWST) (Wednesday, after the market close)
Veru Inc (NASDAQ: VERU) (Thursday, before the market open)
Applied DNA Sciences Inc (NASDAQ: APDN) (Thursday, after the market close)

0



Source : Link

Follow 3-www.NET
Follow
e-News.US
  
Share
e-News.Us

Category Latest Posts